Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- P/B of 7.73 — trading above book value
- Piotroski F-Score 3/9 — signs of financial weakness
- Loss-making — negative ROE of -586.1%
- Revenue growing at 10,429% annually
Dare Bioscience, Inc (DARE) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $22 million . Key value metrics: P/B ratio 7.73, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Dare Bioscience, Inc — Fundamental Analysis Summary
On financial health, DARE shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and negative return on equity of -586.1% (sector average: -19.8%), and high leverage with a debt-to-equity ratio of 9.76.
StockPik's composite Value Score for DARE is 10/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
DARE reports a thin gross margin of -222.2% (sector average: 33.5%) and a negative operating margin of -18,256.1%.
DARE shows revenue growing at 10,429% year-over-year, with earnings declining at 231%.